Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma

20142,247 citationsJournal Articlebronze Open Access

Authors

Héctor Ortega · GlaxoSmithKline (United Kingdom)

Mark C. Liu

Ian Pavord · University of Oxford

Guy Brusselle · Ghent University Hospital

J. Mark FitzGerald

Alfredo Chetta · University of Parma

Marc Humbert · Inserm

Lynn E. Katz ·

Abstract

Mepolizumab administered either intravenously or subcutaneously significantly reduced asthma exacerbations and was associated with improvements in markers of asthma control. (Funded by GlaxoSmithKline; MENSA ClinicalTrials.gov number, NCT01691521.).

Topics & Keywords

Asthma and respiratory diseases Respiratory and Cough-Related Research Chronic Obstructive Pulmonary Disease (COPD) Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 371, Issue 13, pp. 1198-1207

DOI: 10.1056/nejmoa1403290

Field-Weighted Citation Impact: 96.19